^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial
Published date:
01/11/2021
Excerpt:
Patients with activating somatic HER2 mutations with different histologies, including BTC, received neratinib monotherapy….Confirmed ORR in 25 evaluable patients was 12% (95% CI 3–31%) and CBR was 20% (95% CI 7–41%), including 3 confirmed PRs and 2 patients with SD for =16 weeks....Tumor shrinkage was observed in multiple HER2-activating mutations....Median PFS was 2.8 (95% CI 1.1–3.7) months; median overall survival (OS) was 5.4 (95% CI 3.7–11.7) months.
Trial ID:
